Display options
Cite
Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes. JAMA. 2019;321(17):1720-1721doi: 10.1001/jama.2019.2702.
(2019). Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes. JAMA, 321(17), 1720-1721. https://doi.org/10.1001/jama.2019.2702
"Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes." JAMA vol. 321,17 (2019): 1720-1721. doi: https://doi.org/10.1001/jama.2019.2702
Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes. JAMA. 2019 May 07;321(17):1720-1721. doi: 10.1001/jama.2019.2702. PMID: 31063571.
Copy Download .nbib Format: NLM
Share it on

JAMA. 2019 May 07;321(17):1720-1721. doi: 10.1001/jama.2019.2702.

Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes.

JAMA

[No authors listed]

PMID: 31063571 DOI: 10.1001/jama.2019.2702

[No abstract available.]

Publication Types